Technosphere: new drug delivery system for inhaled insulin
نویسندگان
چکیده
منابع مشابه
Technosphere Inhaled Insulin: Is Faster Better?
Pulmonary-delivered insulin is again a reality (1). The failure of the first inhaled insulin in 2007 showed that being radically different from what health care providers are used to, even when injections are avoided, can be problematic. The current product Technosphere inhaled insulin has addressed many of the prior concernsda more convenient delivery device that is dosed in insulin units. Als...
متن کاملPlace of technosphere inhaled insulin in treatment of diabetes
Technosphere insulin (TI), Afrezza, is a powder form of short-acting regular insulin taken by oral inhalation with meals. Action of TI peaks after approximately 40-60 min and lasts for 2-3 h. TI is slightly less effective than subcutaneous insulin aspart, with mean hemoglobin A1c (HbA1c) reduction of 0.21% and 0.4%, respectively. When compared with technosphere inhaled placebo, the decrease in ...
متن کاملPhytosome: Drug Delivery System for Polyphenolic Phytoconstituents
Several plant extracts and phytoconstituents, despite having excellent bioactivity in vitro, demonstrate less or no in vivo actions due to their poor lipid solubility or improper molecular size or destruction in gut. Drug delivery system for polyphenolic phytoconstituents (phytosomes) was prepared by complexing polyphenolic phytoconstituents with phospholipid mainly phosphatidylcholine wh...
متن کاملInhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naı̈ve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents
TI significantly reduced HbA1c by20.8% (29.0 mmol/mol) from a baseline of 8.3% (66.8 mmol/mol) compared with TP 20.4% (24.6 mmol/mol) (treatment difference 20.4% [95% CI 20.57, 20.23]; P < 0.0001). More TI-treated subjects achieved an HbA1c £7.0% (53.0 mmol/mol) (38% vs. 19%; P = 0.002). Mean fasting plasma glucosewas similarly reduced in both groups. Postprandial hyperglycemia, based on 7-poin...
متن کاملNEW DRUG APPROVALS Inhaled Insulin Afrezza For Diabetes
NEW DRUG APPROVALS Inhaled Insulin Afrezza For Diabetes The FDA has approved a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Insulin human inhalation powder (Afrezza, MannKind Corporation) is administered at the beginning of each meal. The product’s safety and effectiveness were evaluated in 3,017 participants—1,026 with type-1 diabetes and 1,991 wit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Future Prescriber
سال: 2012
ISSN: 1468-9871
DOI: 10.1002/fps.90